Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Apr 17;16(1):40.
doi: 10.1186/s13045-023-01436-2.

Emerging evidence and treatment paradigm of non-small cell lung cancer

Si-Yang Maggie Liu #  1 , Mei-Mei Zheng #  2 , Yi Pan  2 , Si-Yang Liu  2 , Yangqiu Li  3   4 , Yi-Long Wu  5   6
Affiliations
Review

Emerging evidence and treatment paradigm of non-small cell lung cancer

Si-Yang Maggie Liu et al. J Hematol Oncol. .

Abstract

Research on biomarker-driven therapy and immune check-point blockade in non-small cell lung cancer (NSCLC) is rapidly evolving. The width and depth of clinical trials have also dramatically improved in an unprecedented speed. The personalized treatment paradigm evolved every year. In this review, we summarize the promising agents that have shifted the treatment paradigm for NSCLC patients across all stages, including targeted therapy and immunotherapy using checkpoint inhibitors. Based on recent evidence, we propose treatment algorithms for NSCLC and propose several unsolved clinical issues, which are being explored in ongoing clinical trials. The results of these trials are likely to impact future clinical practice.

PubMed Disclaimer

Conflict of interest statement

Yi-Long Wu discloses the following personal financial interests: Consulting and advisory services, speaking engagements of Roche, AstraZeneca, Eli Lilly, Boehringer Ingelheim, Sanofi, MSD, and BMS. The other authors have no conflict of interest.

Figures

Fig. 1
Fig. 1
Treatment algorithm for resectable and unresectable NSCLC. Atezo, atezolizumab; nivo, nivolumab; pembro, pembrolizumab; durva, durvalumab; chemo, chemotherapy; CM816, CheckMate816; KN091, KEYNOTE-091
Fig. 2
Fig. 2
Treatment algorithm for advanced NSCLC. Larotrec, larotrectinib; entrec, entrectinib; pembro, pembrolizumab; atezo, atezolizumab; cemip, cemiplimab; toripa, toripalimab; nivo, nivolumab; ipili, ipilimumab; durva, durvalumab; atezo, atezolizumab; tirago, tiragolumab; treme, tremelimumab; sinti, sintilimab; tisle, tislelizumab; camre, camrelizumab; serplu, serplulimab; suge, sugemalimab; chemo, chemotherapy
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72:7–33. doi: 10.3322/caac.21708. - DOI - PubMed
    1. Pao W, Chmielecki J. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer. 2010;10:760–774. doi: 10.1038/nrc2947. - DOI - PMC - PubMed
    1. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947–957. doi: 10.1056/NEJMoa0810699. - DOI - PubMed
    1. Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C, Hu C, Luo Y, Chen L, Ye M, Huang J, Zhi X, Zhang Y, Xiu Q, Ma J, Zhang L, You C. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12:735–742. doi: 10.1016/S1470-2045(11)70184-X. - DOI - PubMed
    1. Wu YL, Planchard D, Lu S, Sun H, Yamamoto N, Kim DW, Tan D, Yang JC, Azrif M, Mitsudomi T, Park K, Soo RA, Chang J, Alip A, Peters S, Douillard JY. Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS. Ann Oncol. 2019;30:171–210. doi: 10.1093/annonc/mdy554. - DOI - PubMed

Publication types

MeSH terms

Substances